Compare Jumia Technologies AG - ADR (JMIA) vs Novartis AG (NVS) Price & Performance

Jumia Technologies AG - ADRTrade

Novartis AGTrade

Price performance (Past 24H)

Key statistics

Jumia Technologies AG - ADR vs Novartis AG — how do they compare? Jumia Technologies AG - ADR trades at $6.3 (market cap $783.99M), while Novartis AG trades at $154.47 (market cap $290.25B). The key difference: Novartis AG is far larger — about 370.2× Jumia Technologies AG - ADR's market cap, and Novartis AG pays a 3.17% dividend while Jumia Technologies AG - ADR pays none. Which is the better fit depends on your goals.

	JMIA	NVS
Market Cap	$783.99M	$290.25B
Sector	Consumer Cyclical	Health
52-Week High	$14.60	$168.62
52-Week Low	$4.45	$113.50
Enterprise Value	$731.09M	$330.27B
Dividend Yield	—	3.17%

View details →View details →

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Jumia Technologies AG - ADR

JMIA trades at $6.36, down 2.15% today, with a bearish technical signal from moving averages. The company shows improving fundamentals with revenue growth to $188.93M in 2025 and narrowing losses, targeting 2027 profitability. Analyst sentiment remains positive with 71% buy ratings despite recent earnings misses. Recent news highlights strong Q1 2026 performance and strategic board appointments.

JMIA presents a high-risk opportunity with significant upside potential if profitability targets are met. The stock faces execution risks in African e-commerce expansion and persistent negative cash flow, but strong revenue growth and analyst support suggest potential for recovery if the 2027 breakeven timeline is achieved.

Novartis AG

No Aura AI signal available yet.

Aura AI is an analytical signal, not financial advice — do your own research.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

JMIA

View details →

NVS

Novartis Q2 earnings expected at $2.17 EPS, $14.07B revenue amid patent loss impact and key drug trials ahead.Gordon Thompson · 18 hours agoNeutral New report details 1,230+ bioinformatics deals, revealing market trends and deal structures through 2026Researchandmarkets.Com · 4 days agoNeutral FDA approves Fabhalta as first drug to significantly slow kidney decline in IgAN patientsNovartis · 4 days agoBullish View details →

About Jumia Technologies AG - ADR

Jumia Technologies AG is the pan-African e-commerce platform. The company's platform consists of a marketplace, which connects sellers with consumers. Its logistics service enables the shipment and delivery of packages from sellers to consumers, and the company's payment service facilitates transactions among participants active on its platform in selected markets. Jumia generates revenue from Sales of goods, Commissions, Fulfillment, Value-added services, and Marketing & Advertising. Its geographical segments are West Africa, North Africa, East & South Africa, Europe, and United Arab Emirates. The firm generates most of its revenue from the West Africa segment.

About Novartis AG

Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.